Sponsor Pipeline

Recursion Pharmaceuticals Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
5
Recruiting
10
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-14 NCT06980116
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell…		 Trial sites expanded: 9 -> 17 locations
Active Trials by Phase
Phase 1/2
3
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT06678659 A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic… Unresectable Recruiting
NCT05552755 Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) Familial Adenomatous Polyposis Recruiting
NCT05985655 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting
Phase 1
NCT07517198 Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors Solid Tumor Recruiting
NCT06980116 Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell… Relapsed or Refractory B-cell Malignancies Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (2) Breast Cancer (2) Triple-Negative Breast Cancer (2) Head & Neck Cancer (2) Leukemia (1) Chronic Lymphocytic Leukemia (CLL) (1) DLBCL (1) Follicular Lymphoma (1) Mantle Cell Lymphoma (1)
Get alerts when Recursion Pharmaceuticals's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free